Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) EBT Margin (2017 - 2025)

Arcus Biosciences has reported EBT Margin over the past 9 years, most recently at 321.21% for Q4 2025.

  • Quarterly results put EBT Margin at 321.21% for Q4 2025, up 3648.0% from a year ago — trailing twelve months through Dec 2025 was 142.91% (down 3361.0% YoY), and the annual figure for FY2025 was 142.91%, down 3361.0%.
  • EBT Margin for Q4 2025 was 321.21% at Arcus Biosciences, up from 519.23% in the prior quarter.
  • Over the last five years, EBT Margin for RCUS hit a ceiling of 79.39% in Q4 2021 and a floor of 824.17% in Q3 2021.
  • Median EBT Margin over the past 5 years was 312.0% (2023), compared with a mean of 353.41%.
  • Peak annual rise in EBT Margin hit 177268bps in 2021, while the deepest fall reached -82700bps in 2021.
  • Arcus Biosciences' EBT Margin stood at 79.39% in 2021, then crashed by -348bps to 197.06% in 2022, then tumbled by -190bps to 571.43% in 2023, then surged by 37bps to 357.69% in 2024, then grew by 10bps to 321.21% in 2025.
  • The last three reported values for EBT Margin were 321.21% (Q4 2025), 519.23% (Q3 2025), and 400.0% (Q1 2025) per Business Quant data.